Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ ...

General and administrative expenses were $5.2 million for the first quarter of 2023 compared to $5.7 million for the first quarter of 2022. The current year decrease resulted primarily from reduced professional fees in 2023. Net cash used in operations was $18.6 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022. Total net cash used was $20.2 million for the first quarter of 2023 compared to $19.3 million for the first quarter of 2022, with the current year increas ...

I will now the call over to Lauren Marek with LifeSci Advisors. Please go ahead. Question-and-Answer Session Company Participants Conference Call Participants Operator Lauren Marek The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10- K, which wil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ___________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39532 Humacyte, Inc. (Exact name of registrant as specified in its charter) ___________________________________ (State or o ...

• November 2022 November 22 Ι 1 Nasdaq: HUMA Universally Implantable Regenerative Human Tissue Disclaimer These slides and the accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included in these slides and the accompanying oral presentation are forward-looking statements reflecting management's current beliefs and expectations. In some cases, you can identify forward-looking statements by terminology such as "will," "anticipate," "ex ...

Humacyte, Inc. (NASDAQ:HUMA) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, IR Laura Niklason - President & CEO Dale Sander - CFO & Chief Corporate Development Officer Conference Call Participants Eric Anderson - Cowen Suraj Kalia - Oppenheimer Bruce Jackson - The Benchmark Company Ryan Zimmerman - BTIG Operator Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2022 Results Conference Call. Currently, all partic ...

Humacyte, Inc. (NASDAQ:HUMA) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, IR Dr. Laura Niklason - President and CEO Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Dr. Heather Prichard - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer Josh Jennings - Cowen Bruce Jackson - The Benchmark Compa ...

Humacyte, Inc. (NASDAQ:HUMA) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Lauren Marek - Investor Relations Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Heather Prichard - Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen and ...

Humacyte, Inc. (NASDAQ:HUMA) Q4 2021 Earnings Conference Call March 29, 2022 8:00 AM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Heather Prichard - Chief Operating Officer Conference Call Participants Josh Jennings - Cowen Ryan Zimmerman - BTIG Brooks O’Neil - Lake Street Capital Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer Bruce Ja ...